Theriva Biologics Inc. (TOVX)

The share price of Theriva Biologics Inc (TOVX) is $1.20 (NYSE) as of 20-Mar-2025 16:10 EDT. Theriva Biologics Inc (TOVX) has given a return of -51.92% in the last 3 years.

Theriva Biologics Inc (TOVX) has a market capitalisation of $ 3 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Theriva Biologics Inc (TOVX) and enter the required number of quantities and click on buy to purchase the shares of Theriva Biologics Inc (TOVX).

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. Address: 9605 Medical Center Drive, Rockville, MD, United States, 20850

The CEO & director of Mr. Steven A. Shallcross CPA. is Theriva Biologics Inc (TOVX), and CFO & Sr. VP is Dr. Vince Wacher Ph.D..

There is no promoter pledging in Theriva Biologics Inc (TOVX).

Some of the close peers are:

No, TTM profit after tax of Theriva Biologics Inc (TOVX) was $0 Mln.